Accepted Article

INTRODUCTION
During thrombosis, the vascular wall is exposed to clotting factors, including the procoagulant protease factor Xa (FXa). FXa is critical convergence point for the intrinsic and extrinsic coagulation pathways. FXa is produced from factor X and catalyze the conversion of pro-thrombin into thrombin during blood coagulation [1] .
Further to its key function as clotting enzyme, FXa also produces effects on the vascular wall suggesting the involvement of FXa as modulator of vascular function. In this regard, and as example, systemic administration of FXa to anesthetized rats caused a hypotensive response associated with the release of nitric oxide from the isolated rat aortic rings [2, 3] . Moreover, in cultured endothelial cells FXa reduced the intracellular calcium transients and stimulated cell proliferation and pro-inflammatory cytokines production [4, 5, 6] .
Patients with type-2 diabetes mellitus have increased risk of cardiovascular events associated with thrombotic and pro-coagulant conditions [7] . In this regard, data have shown that diabetic patients with vascular complications are a diabetic subgroup of patients with increased risk of coagulation disorders and fibrinolysis [8] . In this regard, the vascular wall of diabetic patients with end-stage vasculopathy has higher risk to increase platelet activation. Interestingly, it has been demonstrated that platelets from both experimental diabetic animals and diabetic patients are important source for FXa generation, which may contribute to increase the local concentration of FXa, enhancing the exposition of the diabetic vascular wall to FXa during thrombosis [9] .
The vascular function is a complex processes that it is dependent of several molecular mechanisms and among them vascular energetic metabolism has a relevant role [10] . The arterial wall is supplied with oxygen and nutrients and aerobic glycolysis is considered characteristic of its physiological metabolism [11] . In this regard, it is Accepted Article known that in diabetic patients, abnormalities in vascular energy metabolism contribute to vascular dysfunction and, therefore, to higher risk of cardiovascular events [12] .
Oxidative stress is also closely associated with disturbed coagulation [13] .
Moreover, a close relationship between energy metabolism and oxidative stress has been also postulated. In this regard, mitochondria are not only key in aerobic metabolism but it is also the major site of reactive oxygen species (ROS) production.
Several evidences have associated mitochondrial dysfunction with type-2 diabetes mellitus [14, 15, 16] . However, in our knowledge, oxidative actions of FXa has only been previously reported in human smooth muscle cells from saphenous veins but was not yet explored in the arterial wall of diabetic patients [17] .
Therefore, trying to resemble a coagulating situation, where probably FXa concentration should be locally increased, our aim was to determine if exogenous addition of FXa to femoral arteries from patients with type-2 diabetes mellitus and endstage vasculopathy could modify the expression level of proteins associated with glycolytic metabolism and/or with oxidative stress. [20] . Furthermore, the Rivaroxaban concentration used in the present experiments is clinically relevant [21, 22] . In vitro incubations were follow up for 18 hours and, after that, the femoral arterial segments were collected and stored at -80º C until the molecular determinations were performed.
METHODS
Collection of femoral arteries and in vitro incubations
Two-dimensional (2-DE) electrophoresis and mass spectrometry (MS) analysis.
Femoral arterial samples were homogenized with an Ultra-Turrax T8 IKA-Werke homogenized in a buffer containing 8 mol/L urea, 2% CHAPS w/v, 40 mmol/L dithiothreitol, 0.2% Bio-LyteTH ampholyte (Bio-Rad) and 0.01% W/V bromophenol Accepted Article blue. After incubation in a wheel revolving for 12 hours at 4º C, the homogenate tissues were centrifuged at 10,000 g for 10 min and the supernatant stored at -80ºC until further analysis. Protein determination was performed using bicinchoninic acid reagent (Pierce). Before analysis, samples were submitted to cleanup for isoelectric focusing and 2-DE electrophoresis using a commercial kit, ReadyPrep 2-D Cleanup Kit (BioRad, USA) following the manufacturer instruction. 250 g of total protein was then loaded onto each gel on immobilized gradient IPG strips (pH 3-10) and isoelectric focusing was performed using a Protean IEF cell system (Bio-Rad laboratories) as reported [23] .
In the second dimension, the proteins from femoral arteries were resolved on 10% SDS-PAGE gels using a Protean II XL system (Bio-Rad laboratories) as reported [24] . After electrophoresis, the gels were fixed and silver stained, following manufacturer´s recommendations using a Silver Stain Plus Kit (Bio-Rad laboratories). The gels were then scanned using a UMAX POWERLOOK III Scanner operated by the software Magic Scan V 4.5 and the image analysis was performed using Quantity One 4.2.3
(Bio-Rad Labs). Each spot intensity volume was processed by background subtraction.
For MS, spots were extracted from silver-stained 2-DE gels and digested with sequencegrade modified trypsin (Promega, Madison, WI) as reported [25] . Samples were analyzed using a 4700 Proteomic Analyzer (Applied Biosystem) operated in reflector positive mode. The data generated from spectra were used to identify proteins by peptide mass finger printing, using the MASCOT program and comparing with Mascot database 1.9 (http://www.matrixscience.com). As mentioned in previous works [24, 25] , MS identifications were accepted based on a tripartite evaluation that takes into account significant molecular weight search (worse) scores, spectrum annotation and observed versus expected migration on 2-DE gels.
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Western blot analysis
Protein expression levels of triosephosphate isomerase, pyruvate dehydrogenase, sc-30145, Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA, dilution 1:500).
Lactate dehydrogenase was determined using a monoclonal antibody (sc-133123 Santa
Cruz Biotechnology, dilution 1:100). Pyruvate dehydrogenase was determined by using a polyclonal antibody (PDK1 sc-7140 dilution 1:1000, Santa Cruz Biotechnology Inc USA). CPT-I and CPT-II and gp91-phox NADPH were determined using polyclonal antibodies at dilution 1:1000 purchased from Santa Cruz Biotechnology Inc (sc-20670, sc20526 and sc-5827 respectively). The cytosolic NADPH oxidase gp47-phox and gp67-phox subunits were determined using polyclonal antibodies at dilution 1:1500 purchased from Santa Cruz Biotechnology Inc (sc-14015 and sc-7663 respectively).
The same samples were also incubated with a monoclonal anti-β-actin antibody as loading control. After overnight incubation at 4ºC, nitrocellulose membranes were washed twice and incubated with a peroxidase-conjugated anti-goat IgG antibody (for pyruvate dehydrogenase, CPT-II, and the gp91-phox and gp67-phox NADPH oxidase Accepted Article isotypes), a peroxidase-conjugated anti-rabbit IgG antibody (for triosephosphate isomerase, CPT-I and p47-phox NADPH oxidase) and with an anti-mouse IgG antibody (for lactate dehydrogenase and β-actin), and developed with enhancing chemoluminiscence reagents (ECL; GE Healthcare, Little Chalfont Buckinghamshire, UK).
Determination of lactate, acetyl-Coenzyme A (CoA) and malonyldialdehyde (MDA) content and aconitase activity in the femoral arteries
The content of lactate in the human aortic samples was determined using a lactate assay kits (K607-100; BioVision Incoporated CA,USA) following the manufacturer's instructions.
In the femoral arteries, the content of acetyl-CoA was determined using and double-antibody sandwhich enzyme-linked immunosorbent assay (ELISA) kit (Shanghai Qayee Biotechnology Co., Shanghai, China). MDA content in the femoral arteries was also determined by enzyme immunoassay technique using a commercial kit ( Cloud-Clone Corporation, USA) following the manufacturer´s instructions.
Aconitase activity was determined using a commercial colorimetric assay kit (BioVision Incorporated) following the manufacturer´s instructions.
To determine the content of lactate, acetyl-CoA and MDA content and the aconitase activity in the femoral arteries, 80 g of each homogenized femoral artery was used.
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Statistical analysis.
Results are expressed as mean  EEM. Wilcoxon´s test was used to determine statistical significances. To control the potential antioxidant effects of statin treatment and multivariate linear regression analyses was performed. The dependent variable was the level of MDA content and the level of expression of the oxidative-related proteins in the femoral arteries; the fixed factor was the sample type (control, FXa-and FXa+Rivaroxaban-incubated arteries) and statin treatment was used as covariant. A pvalue<0.05 was considered statistically significant.
RESULTS
Effect of FXa in the level of expression of glycolytic-related proteins in the femoral
arterial wall. Table 1 shows the clinical features of the included patients. All the included patients showed diabetes mellitus and they were not undergone to any antiplatelet and /or anticoagulant treatments from at least 10 days before the femoral artery was obtained. At inclusion, a number of patients were under statin treatment.
In the proteomic analysis the studied spots were those at least expressed in 80% of the 2DE gels within each experiment group. MS analysis was only performed in spots in which statistical differences between control and FXa-incubated arteries were observed. Table 2 shows the MS features of such spots identified in the femoral arteries.
In FXa-incubated femoral arteries the protein expression of two identified triosephosphate isomerase isoforms was increased as compared with those arteries incubated under control conditions (Table 3 ). This greater expression observed in the
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FXa-incubated femoral arteries was further confirmed by Western blot experiments (Figures 1a and 1b) . Moreover, the protein expression of glyceraldehyde-3-phosphate dehydrogenase isoform 1 was also higher in FXa-incubated femoral arteries than in control ( Table 3 ).
The proteomic analysis also revealed that lactate dehydrogenase expression was similar in FXa-incubated femoral arterial segments than in control ( Two isoforms of the mitochondrial precursors of acyl-CoA dehydrogenase, enzyme involved in long-chain fatty acids beta-oxidation, were also identified in the femoral arterial wall, although the protein expression level of none of them were changed by FXa (Table 3) . Moreover, the protein expression level of CPT-I and CPT-II was also determined by Western blotting and they were not significantly different between FXa-incubated and control arteries ( Figures 1A and 1B ).
In the tricarboxylic acid cycle, citrate is converted by aconitase into isocitrate. In the femoral arteries, FXa significantly reduced aconitase activity as compared with control ( Figure 2 ).
The proteomic analysis also showed a higher protein expression level of creatine kinase M chain in FXa-incubated femoral arteries than in control (Table 3 ). The level of expression of other identified energy metabolism-related proteins was not different between control and FXa-incubated arteries (Table 3) .
Effects of Rivaroxaban on the modifications induced by FXa on the glycolytic metabolism.
Addition of Rivaroxaban to FXa-incubated femoral arteries reduced the expression level of triosaphosphate isomerase isoforms 1 and 2 with respect to those arteries incubated with FXa alone (Table 3 and Figures 1A and 1B) . The protein expression level of glyceraldehyde-3-phosphate dehydrogenase isoform 1 was also decreased in the femoral arteries incubated with Rivaroxaban + FXa as compared with FXa alone and it was not statistically different with respect to control (Table 3 ).
In the diabetic femoral arterial wall, addition of Rivaroxaban to FXa did not modify either lactate dehydrogenase expression and lactate content as compared with control and with FXa-incubated arteries (lactate content in Rivaroxaban+FXa-incubated femoral arteries: 18.52 ±02.89 nmol/mg protein).
In Rivaroxaban+FXa-incubated femoral arteries, pyruvate dehydrogenase expression remained reduced with respect to control and even this reduction tended to be more marked than that observed with FXa alone (Figures 1A and 1B) . Moreover, acetyl-CoA content in the Rivaroxaban+FXa-incubated femoral arteries was similar to control and significantly reduced with respect to FXa-incubated arteries (acetyl-CoA content: Rivaroxaban+FXa: 1.39 ± 0.28 pmol/mg arterial protein; p<0.05 with respect to FXa alone).
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Protein expression level of CPT-I and CPT-II was significantly increased in FXa+Rivaroxaban-incubated arteries as compared with both FXa-incubated and control arteries ( Figures 1A and 1B) . In addition, aconitase activity was increased in
FXa+Rivaroxaban-incubated arteries with respect to those incubated with FXa alone (Figure 2) . Finally, the expression of creatine kinase M chain was reduced in the femoral arteries incubated with Rivaroxaban + FXa as compared with those incubated with FXa alone and it was similar to that found in control arteries ( Table 3) . FXa-incubated and control arteries remained significantly increased after adjustement by statin treatment, drug with antioxidant properties, suggesting that the effects of FXa on these parameters were independent of the use of statins (Figures 3 and 4) . However, neither the protein expression level of S-gluthatione transferase nor the two aldehyde dehydrogenase isoforms was different between control and FXa-incubated arteries when in the lineal regression model results were adjusted by statins (Table 4) .
Effects of FXa and
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Addition of Rivaroxaban to FXa reduced the increased protein expression level of either gp91-, gp47-and gp67-phox NADPH oxidase isotypes induced by FXa alone even when the results were adjusted by statin treatment (Figure 3 ). MDA content in the femoral arteries was also reduced in FXa+ Rivaroxaban-incubated femoral arteries as compared with those incubated with FXa alone and this difference remained significative after used statin treatment as covariant (Figure 4) . Glucose metabolism is an important determinant of vascular reactivity [26, 27] .
The present study shows that in the diabetic femoral arterial wall, the level of expression of two triosephosphate isomerase isoforms, a glycolitic key-step enzyme, was significantly increased by FXa as compared with control. FXa also increased the level of expression of an isoform of another one important glycolytic enzyme, glyceraldehyde-3-phosphate dehydrogenase. Initially, these findings might suggest that FXa stimulated the glycolytic pathway in diabetic arteries.
In the arterial wall, the reported stimulation of different molecular mechanisms Apparently, a paradoxical result may be the observation that the acetyl-CoA content increased in FXa-incubated arteries with respect to control since pyruvate dehydrogenase has been downexpressed by FXa. Long-chain fatty acid beta-oxidation is an alternative metabolic pathway to glucose oxidation and also yields acetyl-CoA that then it is catabolized by the tricarboxylic acid cycle. In this regard, circulating levels of free fatty acids have been reported elevated in diabetes because of their excess liberation from adipose tissue and diminished uptake by skeletal muscle [30, 31] .
However, the expression level of two enzymes, CPTI and CPTII, involved in the mitochondrial fatty acid transport a rate-limiting step in long chain fatty acid oxidation.
In addition, the protein expression levels of CPT-I and CPT-II were not modified by Oxidative stress is closely associated not only with energy metabolism and mitochondrial dysfunctionality but also with disturbed coagulation. As example, in hemodialysis patients NADPH oxidase activity was correlated with coagulation priming [34] . Although several evidences have suggested that generation of reactive oxygen species may play an important role in the pathogenesis and complication of diabetes [35, 36] , less is known about the role of FXa on the oxidative stress in the vascular wall.
In this regard, a previous work demonstrated that FXa increased oxidative stress in human vascular smooth muscle cells from saphenous vein [17] . We here showed that in the diabetic femoral arteries, FXa increased the protein expression level of gp 47-phox, 67-phox and gp91-phox NADPH oxidase isotypes, catalytic subunits of cytosolic and Accepted Article mitochondrial NADPH oxidases, supporting pro-oxidative features for FXa. It was further supported by the fact that in the femoral arteries FXa increased the content of MDA, a sign for lipid peroxidation since it is produced during the attack of free radicals to membrane lipoproteins and polyunsaturated fatty acids [37] . Accordingly, increased circulating MDA levels were previously reported in diabetic patients [38] . Therefore, as speculation, FXa may exacerbate oxidative stress in the vascular wall of diabetic patients that may participate in the vascular damage associated with type 2 diabetes mellitus.
The effect of FXa on the expression of these pro-oxidant enzymes and MDA content in the arteries was not modified after adjusted by statin treatment suggesting that these pro-oxidant effects of FXa also occurred in the presence of statins. However, statin treatment affected the apparent modification elicited by FXa on other oxidativerelated proteins such as gluthatione-S-transferase, an antioxidant protein [40] , and two cytosolic aldehyde dehydrogenase, enzyme that oxidize aldehyde to carboxylic acid.
Taken together, these findings may suggest that the presence of statins probably reduced the impact of FXa on the expression of specific oxidative stress-related proteins but not on others.
Effects of Rivaroxaban on the changes induced by FXa
Rivaroxaban although prevented most of the effects of FXa on the energetic metabolism; however, failed to modify FXa-induced pyruvate dehydrogenase downexpression. Since Rivaroxaban specifically inhibits FXa activity, it seems to be difficult to explain it. However, Bono F et al previously demonstrated that the catalytic inactivation of FXa suppressed FXa-induced increase in cytosolic free Ca 2+ but failed to Accepted Article reduce ligand binding of FXa to affect cell protease receptor-1 (EPR-1) [41] . EPR-1 behaves as cofactor for FXa to catalyze prothrombin activation in the absence of FXa.
Interestingly, EPR-1 was reported expressed in endothelial cells [42, 43] . 
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Comments and study limitations
At present, some controversial results exist in the available sparse published data about if FXa was increased or not in diabetic patients [44, 45] . However, it was postulated that diabetic patients showing vascular complications could be a subgroup of diabetic patients with increased risk of coagulation and fibrinolytic disorders [8] .
Moreover, platelets from both experimental diabetic animals and diabetic patients showed higher FXa generation, which additionally it may contribute to greater exposition of the diabetic vascular wall to FXa during thrombosis [9] . Based on these knowledgements, we here only tried to test in vascular wall obtained from diabetic patients with end-stage vasculopathy whether an increased exposition to FXa may modify the protein expression level of energetic metabolism and oxidative-stress-related proteins. Moreover, we must to point out that the here used arterial samples were obtained during leg amputation by thrombosis from diabetic patients with end-stage vasculopathy. It is important to point out that there was not any other practical way to obtain such type of tissues. Therefore, the present findings should be only considered for the type of arterial samples here tested.
An observation extracted from the present findings was that Rivaroxaban might exert additional effects non-related to FXa, since FXa by itself did not modify the expression of CPT-I and CPT-II in the diabetic femoral arteries but it was increased in presence of Rivaroxaban [46] . In this regard, it has been reported the existence of Rivaroxaban-derivated metabolites. Therefore, we can not discard that the observed effect of Rivaroxaban on CPT-I and CPT-II expression could due to Rivaroxaban by itself but also by its identified metabolites. Although it seems to be an interesting observation, at present it is out of the scope of the present study and further experiments are needed to clarify it. Accepted Article 
Accepted Article
This article is protected by copyright. All rights reserved. 
